E-drug: Essential Drugs Monitor subscribing information
-------------------------------------------------------------------------
[After receiving WHO's Essential Drugs Monitor this morning, I
thought there might be more E-druggers interested in receiving it. I
contacted the Editor and she asked me to circulate the subscription
form (below). The Essential Drugs Monitor is distributed free of
charge. Which quality journal beats that? HH]
------------------------
The Essential Drugs Monitor is produced and distributed by the
World Health Organization Department of Essential Drugs and
Medicines Policy. It is published in Chinese, English, French,
Russian and Spanish and is free of charge with a global readership
of some 250 000. The Monitor carries news of developments in
national drug policies, therapeutic guidelines, current
pharmaceutical issues, educational strategies and operational
research.
If you would like to subscribe to the Monitor please complete the
form below and return it by e-mail, fax, or snailmail to:
EDM Documentation Centre, Essential Drugs and Medicines Policy,
World Health Organization, 20 avenue Appia, CH-1211 Geneva 27,
Switzerland. Tel: + 41 22 791 3521, Fax: + 41 22 791 4167,
e-mail: edmdoccentre@who.int
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
:::::::::::::::
I would like to subscribe to the Essential Drugs Monitor and receive
regular copies in one language free of charge
Name .....................................
Agency .....................................
Profession .....................................
Address .....................................
.....................................
Country .....................................
Language required (please indicate):
0 Chinese
0 English
0 French
0 Russian
0 Spanish
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://satellife.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.